Safety of AI-Powered Virtual Assistant in Outpatient Management of Heart Failure

ConditionHeart Failure
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorEast and North Hertfordshire NHS Trust

About this trial

The aim of this pilot randomized study is to examine whether integrating the SIRIO-HF virtual assistant (VA) into the outpatient management of participants recently discharged from hospital with a new diagnosis of heart failure (HF), may reduce the need for regular medical assessment and the healthcare burden, reduce variability in healthcare, and meet with participant satisfaction, without compromising participant safety and overall care quality.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years

Newly diagnosed HF with New York Heart Association class II-III symptoms at discharge

Disqualifiers

Known prior history of HF

Severe comorbidities that could affect protocol adherence, in the opinion of the investigator

Alternative diagnosis for symptoms such as chronic obstructive pulmonary disease

Dementia or other cognitive impairment

Trial design

Design model

Single group

Treatments tested in this trial

  • HF-guided VA

    Other intervention

    VA guided recommendation

  • Standard-of-care

    Other intervention

    Standard-of-care

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: VA-guided armExperimental treatment 1 intervention
Group B: Standard-of-care armPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Acceptability of the intervention to users (participants)

This will be assessed utilising an adapted 'acceptability of intervention measure' (AIM)

Time frame
12 weeks

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

East and North Hertfordshire NHS Trust

Lead sponsor

Clinical and Interventional Cardiology, Sassari University Hospital, Sassari, Italy

Collaborator